JAMENT 1638

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mukerji et al.

Serial No.: 10/060,793

Filed: January 30, 2002

For: DESATURASE GENES, ENZYMES

ENCODED THEREBY AND USES

THEREOF

Case No.: 6884.US.01

Examiner: McElwain, E.F.

Group Art Unit: 1638

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date of Deposit:

Kimberly A. Iorio

## TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF are the following:

- 1. Response to Notice to Comply and Supplemental Preliminary Amendment (5 Pages);
- Copy of Notice to Comply (1 Page);
- 3. Substitute Paper Copy of the Sequence Listing (26 Pages);
- 4. Substitute Computer Readable Form Copy (1 Diskette);
- 5. Statement to Support Filings and Submissions in Accordance with 35 CFR §§1.821-1.825 (1 Page); and
- 6. Return Receipt Postcard.
- The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Mukerji, et al.


ABBOTT LABORATORIES Customer No.: 23492

Telephone: (847) 938-7576 Facsimile: (847) 938-2623 Cheryl L. Becker

Registration No. 35,441 Attorney for Applicants

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. other: See the attacked page regarding sequences in the specification not included in the CRF

## Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.